What did Reuters report about Ozempic’s list price in March 2023?
Reuters reported that the U.S. list price for Ozempic was $935.77 per month in March 2023. This figure refers to the drug’s posted “list price,” which can differ from what patients actually pay after insurance coverage, pharmacy benefit manager (PBM) pricing, and rebates.
Is that $935.77 the actual amount patients pay?
Usually not. U.S. “list price” is the publicly posted price and often does not match:
- the net price paid by insurers and PBMs,
- the negotiated price at the pharmacy,
- or the patient’s out-of-pocket cost (which depends on insurance, deductibles, copays, and eligibility for discount programs).
Why might Ozempic’s list price matter to news coverage?
List-price reporting is often used to track changes in manufacturer pricing over time and to help explain why costs can rise even when the clinical use of a drug stays the same. It also provides a baseline for comparisons across sources that report different “prices” (list price vs. net price vs. cash price).
Where can I verify the specific Reuters figure?
If you need the exact line from the March 2023 Reuters article (and the context around it), share the Reuters link or the headline/date you’re referring to, and I can help extract the relevant details.
Sources
- [1] DrugPatentWatch.com (price/patent tracking context): https://www.drugpatentwatch.com